Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Cytogenetics

Immunohistochemistry Progesterone Receptor PR Test

The Immunohistochemistry Progesterone Receptor (PR) Test assesses hormone receptor status in tumor tissue, primarily used in breast cancer diagnosis and treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue in 10% formal-saline or formalin-fixed paraffin embedded block.
Results
Sample Daily by 6 PM. Report Block: 5 days. Tissue Biopsy: 5 days. Tissue Large Complex: 7 days. Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the specimen is correctly labeled and accompanied by a copy of the Histopathology report, biopsy site information, and relevant clinical history.
Test priceKSh 3,416

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry Progesterone Receptor PR Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of breast cancer.
  • ✓Treatment planning for breast cancer.
  • ✓Assessment of prognosis in breast cancer.
  • ✓Monitoring response to hormone therapy.
  • ✓Evaluation of hormone receptor status in certain other cancers.
02

In plain language

What this test helps you understand

This test helps determine if a patient's cancer cells are likely to respond to hormone therapy targeting progesterone receptors. It aids in prognosis assessment and guides personalized treatment strategies for hormone-receptor-positive cancers.
The Immunohistochemistry Progesterone Receptor (PR) Test is a crucial diagnostic procedure used mainly in oncology. This test evaluates the presence of progesterone receptors in tumor tissues. Understanding the hormone receptor status is vital for determining the behavior of certain cancers, especially breast cancer. By identifying the presence of these receptors, healthcare providers can tailor treatment plans that are more effective for individual patients. This test specifically measures the expression of progesterone receptors in tumor cells. A positive result indicates that the cancer cells are likely to respond to hormone therapy, while a negative result may suggest alternative treatment options. This test is essential for oncologists and pathologists to guide treatment decisions effectively.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the specimen is correctly labeled and accompanied by a copy of the Histopathology report, biopsy site information, and relevant clinical history.
SampleTumor tissue in 10% formal-saline or formalin-fixed paraffin embedded block.
MethodologyImmunohistochemistry (IHC) using specific antibodies to detect progesterone receptors in tissue sections.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
The test results reflect the receptor status of the specific tissue sample provided. Heterogeneity within tumors can sometimes lead to discrepancies between samples. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The test determines if cancer cells have progesterone receptors, helping doctors decide if hormone therapy will be effective.
A sample of tumor tissue, either in formalin-saline or a formalin-fixed paraffin embedded block, is required.
Turnaround time varies depending on the sample type, typically ranging from 5 to 7 days. Confirm with the laboratory before booking.
A positive result indicates the presence of progesterone receptors, suggesting the cancer may respond to hormone therapy.
No specific patient preparation is required for this test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Catecholamines Plasma Test

Measures epinephrine and norepinephrine levels in plasma to help detect hormonal imbalances related to conditions like hypertension and anxiety. Confirm with the laboratory before booking.

Learn more →

Epstein-Barr Virus Early RNA EBERISH In Situ Hybridization Test

Detects Epstein-Barr Virus (EBV) RNA in tumor tissue to aid in the early diagnosis of EBV-related cancers like lymphomas and nasopharyngeal carcinoma.

Learn more →

CA Cyfra 211 Lung Cancer Marker Test

The CA Cyfra 21-1 Lung Cancer Marker Test measures a specific protein fragment in the blood that can be elevated in lung cancer. It aids in diagnosis and monitoring.

Learn more →

Breast Cancer ER PR HER2 Ki67

The Breast Cancer ER PR HER2 Ki67 test analyzes key markers in breast tumor tissue to guide personalized treatment decisions. It measures hormone receptors (ER, PR), HER2 protein, and the Ki-67 proliferation marker.

Learn more →
Chat on WhatsApp